Target intelligence / Profile preview

Hantaan virus and Puumala virus envelope glycoproteins Gn and Gc (HTNV Gn-Gc and PUUV Gn-Gc)

Target
HTNV Gn-Gc and PUUV Gn-Gc
Molecular classification
Viral envelope protein, Type I transmembrane protein, Glycoprotein
01

Overview

The Hantaan virus (HTNV) and Puumala virus (PUUV) Gn and Gc glycoproteins are the essential surface proteins of these orthohantaviruses, which are the primary causative agents of hemorrhagic fever with renal syndrome (HFRS) in Eurasia (PMID: 30715428). These glycoproteins are encoded by the viral M genomic segment and are synthesized as a precursor polyprotein that is co-translationally cleaved into Gn and Gc subunits (UniProt: P08668, P23457). On the viral envelope, they assemble into spikes that mediate attachment to host cell receptors, such as beta-3 integrins, and facilitate membrane fusion following endocytosis (PMID: 24501065). As the primary targets for the host's neutralizing antibody response, these glycoproteins are the central components of vaccine candidates, including bivalent DNA vaccines like pHTN-M and pPUU-M, which have been evaluated in clinical trials (PMID: 24501065). Targeting both HTNV and PUUV glycoproteins is a strategic approach to provide broad-spectrum protection against various hantavirus strains that cause HFRS across different geographic regions.

Other names
Hantaan virus G1 and G2 proteinsPuumala virus G1 and G2 proteinsHantavirus M segment glycoproteinsHTNV Gn/GcPUUV Gn/GcOrthohantavirus envelope glycoproteins
02

Mechanism of action

Induction of neutralizing antibodies that bind to the Gn and Gc surface glycoproteins, preventing viral attachment to host cell receptors and inhibiting pH-dependent membrane fusion (PMID: 30715428).

03

Biological functions

Viral attachmentMembrane fusionReceptor bindingViral entry
04

Disease associations

Hemorrhagic fever with renal syndrome (HFRS)Nephropathia epidemicaInfection
05

Safety considerations

Potential for antibody-dependent enhancement (ADE)Injection site reactionsSystemic flu-like symptoms following vaccinationLimited cross-protection against non-targeted hantavirus species
06

Interacting drugs

Hantavax

3 more in the full profile.

07

Biomarkers

Neutralizing antibody titers (PRNT50)Anti-Gn/Gc specific IgG levelsViral RNA load

Beyond the preview

Go deeper on Hantaan virus and Puumala virus envelope glycoproteins Gn and Gc (HTNV Gn-Gc and PUUV Gn-Gc).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hantaan virus and Puumala virus envelope glycoproteins Gn and Gc (HTNV Gn-Gc and PUUV Gn-Gc).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call